Previous close | 0.2500 |
Open | 0.2500 |
Bid | 0.0500 |
Ask | 0.2000 |
Strike | 250.00 |
Expiry date | 2024-01-19 |
Day's range | 0.2500 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 290 |
Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. Vertex is a much larger company with proven innovative abilities, and it has generated strong and consistent revenue, earnings, and stock-market performance in the past decade. CRISPR is a much younger company with a much shorter track record, but could it one day become as successful as its larger partner?
Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...